ymjЯкутский медицинский журналYakut Medical Journal1813-19052312-1017ЯНЦ КМП10.25789/YMJ.2022.78.30ymj-150Research ArticleНАУЧНЫЕ ОБЗОРЫ И ЛЕКЦИИSCIENTIFIC REVIEWS AND LECTURESИммуномодулирующие свойства ангиогенных факторов и миелоидных супрессорных клеток: роль в гестационном процессеImmunomodulatory properties of angiogenic factors and myeloid suppressor cells: a role in the gestational processhttps://orcid.org/0000-0002-6757-3896ХонинаН. А.KhoninaN. A.

Хонина Наталья Алексеевна – д.м.н., в.н.с.; проф.

Khonina Natalia A. – M.D., leading researcher, laboratory of cellular immunotherapy;  professor of Institute of Medicine and Psychology

Novosibirsk

nkhonina@mail.ruФедороваА. В.FedorovaA. V.

Федорова Анастасия Валерьевна – ординатор 2 года

Fedorova Anastasia V. - intern

Novosibirsk

acechka@yandex.ruhttps://orcid.org/0000-0001-6585-3213СметаненкоЕ. А.SmetanenkoE. A.

Сметаненко Екатерина Александровна – аспирант 3 года

Smetanenko Ekatarina A. - post-graduate student, laboratory of cellular immunotherapy

Novosibirsk

alekta5@yandex.ruhttps://orcid.org/0000-0002-6095-1954ПасманН. М.PasmanN. M.

Пасман Наталья Михайловна – д.м.н., проф., зав. кафедрой

Pasman Natalia M. –M.D., head of Department of Obstetrics and Gynecology of Institute of Medicine and Psychology

Novosibirsk

nmpasman@gmail.comhttps://orcid.org/0000-0003-2346-6279ЧерныхЕ. Р.ChernykhE. R.

Черных Елена Рэмовна – д.м.н., проф., член-корр. РАН, зав. лаб.

Chernykh Elena R. – M.D., professor, Corresponding Member of the Russian Academy of Sciences, head of laboratory of cellular immunotherapy

Novosibirsk

ct_lab@mail.ruФГБНУ «НИИ фундаментальной и клинической иммунологии»; Институт медицины и психологии НГУРоссияInstitute of Fundamental and Clinical Immunology; Novosibirsk State UniversityRussian FederationФГБНУ «НИИ фундаментальной и клинической иммунологии»РоссияInstitute of Fundamental and Clinical Immunology, embryologist of Clinic PasmanRussian FederationНГУРоссияNovosibirsk State UniversityRussian FederationФГБНУ «НИИ фундаментальной и клинической иммунологии»РоссияInstitute of Fundamental and Clinical ImmunologyRussian Federation20220402202502117120Copyright © Хонина Н.А., Федорова А.В., Сметаненко Е.А., Пасман Н.М., Черных Е.Р., 20252025Хонина Н.А., Федорова А.В., Сметаненко Е.А., Пасман Н.М., Черных Е.Р.Khonina N.A., Fedorova A.V., Smetanenko E.A., Pasman N.M., Chernykh E.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ymj.elpub.ru/jour/article/view/150

В обзоре представлены данные об иммуномодулирующей роли ангиогенных факторов и миелоидных супрессорных клеток. Показаны механизмы, играющие ключевую роль в формировании баланса про- и антиангиогенных факторов, значение фактора роста эндотелия (VEGF), плацентарного ростового фактора (PlGF) и миелоидных супрессорных клеток (MDSC, MС) в развитии гестационной иммуносупрессии. Представлены данные о молекулярных механизмах иммуносупрессии, экспрессии чек-поинт молекул, которые играют главную роль в подавлении реакций клеточного иммунитета. Охарактеризована роль тирозинкиназных рецепторов для белков семейства VEGF - VEGF-1 (Flt-1), VEGFR-2 (KDR/Flk-1) в регуляции иммунных реакций. Представлены данные о кроссрегуляторном взаимодействии ангиогенных факторов и миелоидных супрессорных клеток и иммуномодулирующем влиянии на реакции клеточного иммунитета. Нарушение данных механизмов может быть связано с развитием гестационных осложнений, в частности преэклампсии. На основании представленных данных рассматривается возможность оценки VEGF и MС у беременных как прогностического маркера развития гестационных осложнений.

The review presents data on the immunomodulatory role of angiogenic factors and myeloid suppressor cells. The mechanisms that play a key role in shaping the balance of proangiogenic and antiangiogenic factors, the role of endothelial growth factor (VEGF), placental growth factor (PlGF) and myeloid suppressor cells (MDSC, MS) in the development of gestational immunosuppression are shown. Data are presented on the molecular mechanisms of immunosuppression, the expression of check-point molecules that play a major role in the suppression of cellular immunity reactions. The role of tyrosine kinase receptors for proteins of the VEGF family - VEGF-1 (Flt-1), VEGFR-2 (KDR/Flk-1) in the regulation of immune responses has been characterized. Data are presented on the cross-regulatory interaction of angiogenic factors and myeloid suppressor cells and the immunomodulatory effect on cellular immunity responses. Disturbance of these mechanisms may be associated with the development of gestational complications, in particular preeclampsia. Based on the presented data, the possibility of evaluating VEGF and MS in pregnant women as prognostic biomarkers of preeclampsia is considered.

фактор роста эндотелия сосудов (VEGF)плацентарный фактор роста (PlGF)миелоидные супрессорные клетки (MDSCМС)преэклампсияvascular endothelial growth factor (VEGF)placental growth factor (PlGF)myeloid suppressor cells (MDSC)preeclampsiaReferencesПреэклампсия сегодня: патогенез и возможности прогнозирования и лечения / А.Н. Стрижаков, Е.В. Тимохина, Е.Г. Пицхелаури [и др.] // Вопросы гинекологии, акушерства и перинатологии. – 2016. – Т. 15, № 3. – С. 24-31.Strizhakov A.N., Timokhina E.V., Pitskhelauri E.G. [et al.]. Preeclampsia today: pathogenesis and possibilities of prediction and treatment Issues of gynecology, obstetrics and perinatology. 2016;15( 3): 24-31.Сигналинг через рецептор к фактору роста эндотелия сосудов 1-го типа как новый механизм подавления Т-клеток при опухолевом неоангиогенезе / Е.Р. Черных, О.Ю. Леплина, М.А. Тихонова [и др.] // Мед. иммунология. - 2019.- Т. 21, № 4.- С. 653-660. doi. org/10.15789/1563-0625-2019-4.Chernykh E.R., Leplina O.Yu., Tikhonova M.A. [et al.]. Vascular endothelial growth factor receptor-1 signaling as a novel mechanism of t cell suppression in tumor neoangiogenesis. Medical Immunology. 2019; 21(4): 653-660.]Фактор роста плаценты модулирует ответ активированных invitroT-клеток / Е.А. Сметаненко, О.Ю. Леплина, М.А. Тихонова [и др.] // Бюллетень сибирской медицины. – 2020. - Т. 19, № 4.- С. 158-166. doi: 10.20538/1682-0363-2020-4-158-166.Smetanenko E.A., Leplina O.Yu., Tikhonova M.A. [et al.]. Placental growth factor modulates the response of in vitro activated T cells. Bulletin of Siberian Medicine.2020;19(4): 158-166.] doi: 10.20538/1682-0363-2020-4-158-166.Angiogenic Marker Prognostic Models in Pregnant Women With Hypertension / Perry H., Binder J., Kalafat E. [et al.] // Hypertension.- 2020.-V.75.-P. 755–761Angiogenic Marker Prognostic Models in Pregnant Women With Hypertension / Perry H., Binder J., Kalafat E. [et al.] // Hypertension.- 2020.-V.75.-P. 755–761Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment / N. Horikawa, K. Abiko, N. Matsumura [et al.] // Br J Cancer. 2020-V. 122(6).-P.778-788. doi: 10.1038/s41416-019-0725-x.Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment / N. Horikawa, K. Abiko, N. Matsumura [et al.] // Br J Cancer. 2020-V. 122(6).-P.778-788. doi: 10.1038/s41416-019-0725-x.Association between Placental Lesions, Cytokines and Angiogenic Factors in Pregnant Women with Preeclampsia / I.C. Weel, R.N. Baergen, M. Romão-Veiga [et al.] // PLOS ONE.- 2016.- V. 11, № 6.Association between Placental Lesions, Cytokines and Angiogenic Factors in Pregnant Women with Preeclampsia / I.C. Weel, R.N. Baergen, M. Romão-Veiga [et al.] // PLOS ONE.- 2016.- V. 11, № 6.Bergenfelz C. The Generation and Identity of Human Myeloid-Derived Suppressor Cells / Bergenfelz C., Leandersson K.// Front. Oncol.-2020.-V. 10: 109. doi.org/10.3389/fonc.2020.00109.Bergenfelz C. The Generation and Identity of Human Myeloid-Derived Suppressor Cells / Bergenfelz C., Leandersson K.// Front. Oncol.-2020.-V. 10: 109. doi.org/10.3389/fonc.2020.00109.Binding of the placental growth factor to VEGF receptor type 1 modulates human T cell functions / O.Yu. Leplina, E. Smetanenko, M. Tikhonova [et al.] //J Leukoc Biol.- 2020-V.108.-P.1013-1024. doi: 10.1002/JLB.2A0420-723RRBinding of the placental growth factor to VEGF receptor type 1 modulates human T cell functions / O.Yu. Leplina, E. Smetanenko, M. Tikhonova [et al.] //J Leukoc Biol.- 2020-V.108.-P.1013-1024. doi: 10.1002/JLB.2A0420-723RRCirculating levels of angiogenic factors and their association with preeclampsia among pregnant women at Mulago National Referral Hospital in Uganda / Nabweyambo S., Sande O.J., McGovern N. [et al.] // PLOS ONE.-2021. doi. org/10.1371/ journal. pone. 0251227.Circulating levels of angiogenic factors and their association with preeclampsia among pregnant women at Mulago National Referral Hospital in Uganda / Nabweyambo S., Sande O.J., McGovern N. [et al.] // PLOS ONE.-2021. doi. org/10.1371/ journal. pone. 0251227.Circulating soluble fms-like tyrosine kinase-1, soluble endoglin and placental growth factor during pregnancy in normotensive women in KwaZulu-Natal, South Africa / M. Ogunlola, P. Reddy, M.N. Sibiya [et al.] // Afr Health Sci.- 2019.- V. 19.-P.1821-1832.Circulating soluble fms-like tyrosine kinase-1, soluble endoglin and placental growth factor during pregnancy in normotensive women in KwaZulu-Natal, South Africa / M. Ogunlola, P. Reddy, M.N. Sibiya [et al.] // Afr Health Sci.- 2019.- V. 19.-P.1821-1832.Continuous activation of polymorphonuclear myeloid-derived suppressor cells during pregnancy is critical for fetal development ./ Shi M., Chen Z,. Chen M. [et al.] // Cell Mol Immunol.- 2021.-V.18 (7).-P.1692-1707. doi: 10.1038/s41423-021-00704-wContinuous activation of polymorphonuclear myeloid-derived suppressor cells during pregnancy is critical for fetal development ./ Shi M., Chen Z,. Chen M. [et al.] // Cell Mol Immunol.- 2021.-V.18 (7).-P.1692-1707. doi: 10.1038/s41423-021-00704-wDirect and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment / Bourhis M., Palle J., Galy-Fauroux I. [et al.] //Front Immunol.- 2021.-12:616837.doi. org/10.3389/ fimmu. 2021. 616837.Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment / Bourhis M., Palle J., Galy-Fauroux I. [et al.] //Front Immunol.- 2021.-12:616837.doi. org/10.3389/ fimmu. 2021. 616837.Gabrilovich D.I. /Myeloid-derived suppressor cells / D.I. Gabrilovich//Cancer Immunol Res.- 2017.- V. 5, N. 1.- P. 3-8. doi:10.1158/2326-6066. CIR-16-0297.Gabrilovich D.I. /Myeloid-derived suppressor cells / D.I. Gabrilovich//Cancer Immunol Res.- 2017.- V. 5, N. 1.- P. 3-8. doi:10.1158/2326-6066. CIR-16-0297.Gardner A. Dendritic cells and cancer immunity / A. Gardner, B. Ruffell// Trends Immunol. - 2016.- V. 37.- P. 855–65.Gardner A. Dendritic cells and cancer immunity / A. Gardner, B. Ruffell// Trends Immunol. - 2016.- V. 37.- P. 855–65.Granulocytic Myeloid-Derived Suppressor Cells Accumulate in Human Placenta and Polarize toward a Th2 Phenotype / N. Kostlin, K.Hofstadter, A.L. Ostermeir [et al.] //J Immunol.- 2016.-V.196(3).-P.1132–45. doi: 10.4049/jimmunol.1500340.Granulocytic Myeloid-Derived Suppressor Cells Accumulate in Human Placenta and Polarize toward a Th2 Phenotype / N. Kostlin, K.Hofstadter, A.L. Ostermeir [et al.] //J Immunol.- 2016.-V.196(3).-P.1132–45. doi: 10.4049/jimmunol.1500340.Immature CD11b + Gr1+ myeloid cells that acquire immunosuppressive capability, also known as myeloid-derived suppressor cells (MDSCs), are a heterogeneous population of cells that regulate immune responses / M.P. Udumula, S. Sakr, S. Dar [et al.] // MolMetab.- 2021.- 53:101272. doi: 10.1016/j.molmet.2021.101272.Immature CD11b + Gr1+ myeloid cells that acquire immunosuppressive capability, also known as myeloid-derived suppressor cells (MDSCs), are a heterogeneous population of cells that regulate immune responses / M.P. Udumula, S. Sakr, S. Dar [et al.] // MolMetab.- 2021.- 53:101272. doi: 10.1016/j.molmet.2021.101272.Jim B. Preeclampsia: Pathogenesis, Prevention, and Long-Term Complications / B.Jim, S.A. Karumanchi // Semin Nephrol. - 2017.- V. 37.-P. 386–397.Jim B. Preeclampsia: Pathogenesis, Prevention, and Long-Term Complications / B.Jim, S.A. Karumanchi // Semin Nephrol. - 2017.- V. 37.-P. 386–397.Kostlin-Gille N. Myeloid-Derived Suppressor Cells in Pregnancy and the Neonatal Period / N.C. Kostlin-Gille N, C.Gille // Front. Immunol.- 2020.-V.11, 584712.Kostlin-Gille N. Myeloid-Derived Suppressor Cells in Pregnancy and the Neonatal Period / N.C. Kostlin-Gille N, C.Gille // Front. Immunol.- 2020.-V.11, 584712.Kowalska W. Monocytic MDSC as a source of immunosuppressive cytokines in chronic lymphocytic leukemia (CLL) microenvironment / W. Kowalska, A. Bojarska-Junak // Folia HistochemCytobiol.- 2020.-V. 58 (1).-P.25-36. doi: 10.5603/FHC.a2020.0006.Kowalska W. Monocytic MDSC as a source of immunosuppressive cytokines in chronic lymphocytic leukemia (CLL) microenvironment / W. Kowalska, A. Bojarska-Junak // Folia HistochemCytobiol.- 2020.-V. 58 (1).-P.25-36. doi: 10.5603/FHC.a2020.0006.Lecarpentier E. Angiogenic balance (sFlt-1/PlGF) and preeclampsia / E. Lecarpentier, V. Tsatsari // Ann Endocrinol.- 2016.- V. 77.- P. 97-100.Lecarpentier E. Angiogenic balance (sFlt-1/PlGF) and preeclampsia / E. Lecarpentier, V. Tsatsari // Ann Endocrinol.- 2016.- V. 77.- P. 97-100.Maternal Serum Angiogenic Factor sFlt-1 to PlGF Ratio in Preeclampsia: A Useful Marker for Differential Diagnosis and Prognosis Evaluation in Chinese Women / W-Z. Lou, F. Jiang, J. Hu [et al.] // Dis Markers.- 2019:6270187–.10.1155/2019/6270187.Maternal Serum Angiogenic Factor sFlt-1 to PlGF Ratio in Preeclampsia: A Useful Marker for Differential Diagnosis and Prognosis Evaluation in Chinese Women / W-Z. Lou, F. Jiang, J. Hu [et al.] // Dis Markers.- 2019:6270187–.10.1155/2019/6270187.Mellor A.L. Indoleamine 2,3-Dioxygenase and Tolerance: Where Are We Now? /A.L. Mellor, H. Lemos, L.Huang // Front. Immunol.- 2017.- https:// doi.org/10.3389/fimmu. 2017.01360.Mellor A.L. Indoleamine 2,3-Dioxygenase and Tolerance: Where Are We Now? /A.L. Mellor, H. Lemos, L.Huang // Front. Immunol.- 2017.- https:// doi.org/10.3389/fimmu. 2017.01360.Ming Y. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment / Y. Ming, J. Dechao, Q. Shuang // Mol Cancer.- 2019.- V. 18, 60.Ming Y. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment / Y. Ming, J. Dechao, Q. Shuang // Mol Cancer.- 2019.- V. 18, 60.Multifaceted Role of the Placental Growth Factor (PlGF) in the Antitumor Immune Response and Cancer Progression / L. Albonici, M.G. Giganti, A. Modesti [et al.] // Int J Mol Sci.- 2019.-V. 20(12).-P. 2970. doi: 10.3390/ijms20122970Multifaceted Role of the Placental Growth Factor (PlGF) in the Antitumor Immune Response and Cancer Progression / L. Albonici, M.G. Giganti, A. Modesti [et al.] // Int J Mol Sci.- 2019.-V. 20(12).-P. 2970. doi: 10.3390/ijms20122970Myeloid-derived suppressor Cells (MDSC): When good intentions go awry./ Sanchez-Pino M.D., Dean M.J., A.C. Ochoa // Cell Immunol. - 2021.- V. 362:104302/ doi: 10.1016/j.cellimm.2021. 104302.Myeloid-derived suppressor Cells (MDSC): When good intentions go awry./ Sanchez-Pino M.D., Dean M.J., A.C. Ochoa // Cell Immunol. - 2021.- V. 362:104302/ doi: 10.1016/j.cellimm.2021. 104302.Pawelec G. Myeloid-Derived Suppressor Cells: Not Only in Tumor Immunity / G. Pawelec, C.P. Verschoor, S. Ostrand-Rosenberg // Front Immunol. – 2019.- V.10:1099. doi: 10.3389/ fimmu.2019.01099.Pawelec G. Myeloid-Derived Suppressor Cells: Not Only in Tumor Immunity / G. Pawelec, C.P. Verschoor, S. Ostrand-Rosenberg // Front Immunol. – 2019.- V.10:1099. doi: 10.3389/ fimmu.2019.01099.PlGF Immunological Impact during Pregnancy./Albonici L, Benvenuto M, Focaccetti C. [et al.] // Int J Mol Sci.- 2020.-V. 21(22):8714. doi: 10.3390/ijms21228714.PlGF Immunological Impact during Pregnancy./Albonici L, Benvenuto M, Focaccetti C. [et al.] // Int J Mol Sci.- 2020.-V. 21(22):8714. doi: 10.3390/ijms21228714.Roskoski R.Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas / R. Roskoski // Pharmacol Res.- 2017.- V.120.-P. 116–132.Roskoski R.Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas / R. Roskoski // Pharmacol Res.- 2017.- V.120.-P. 116–132.Tesi R.J. MDSC; the Most Important Cell You Have Never Heard Of. /R.J. Tesi // Trends Pharmacol Sci.- 2019.- 40(1).-P.4-7. doi: 10.1016/j.tips.2018.10.008.Tesi R.J. MDSC; the Most Important Cell You Have Never Heard Of. /R.J. Tesi // Trends Pharmacol Sci.- 2019.- 40(1).-P.4-7. doi: 10.1016/j.tips.2018.10.008.Limagne E., Richard C., Marion Thibaudin M. [et al.]. Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients. Oncoimmunology.- 2019.-V. 8(4): e1564505 doi: 10.1080/2162402X. 2018.1564505.Limagne E., Richard C., Marion Thibaudin M. [et al.]. Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients. Oncoimmunology.- 2019.-V. 8(4): e1564505 doi: 10.1080/2162402X. 2018.1564505.Ullah К. Hypoxia-Inducible Factor Regulates Endothelial Metabolism in Cardiovascular Disease / K. Ullah, R. Wu // Front Physiol.- 2021.- V. 12: 670653. Published online 2021 Jul 5. doi: 10.3389/fphys. 2021.670653.Ullah К. Hypoxia-Inducible Factor Regulates Endothelial Metabolism in Cardiovascular Disease / K. Ullah, R. Wu // Front Physiol.- 2021.- V. 12: 670653. Published online 2021 Jul 5. doi: 10.3389/fphys. 2021.670653.Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis / C.S. Melincovici, A.B. Boşca, S. Şuşman [et al.]// Rom J Morphol Embryol.- 2018.- V. 59.- P. 455-467.Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis / C.S. Melincovici, A.B. Boşca, S. Şuşman [et al.]// Rom J Morphol Embryol.- 2018.- V. 59.- P. 455-467.Yadav L. Tumour Angiogenesis and Angiogenic Inhibitors: A Review / L.Yadav //J clindiagn res. – 2015.- V. 9.- P.XE01-XE05.Yadav L. Tumour Angiogenesis and Angiogenic Inhibitors: A Review / L.Yadav //J clindiagn res. – 2015.- V. 9.- P.XE01-XE05.Yang J. Targeting VEGF/VEGFR to Modulate Antitumor Immunity / J. Yang, J. Yan, B. Liu // Front. Immunol.- 2018.- V.9.- P. 978.Yang J. Targeting VEGF/VEGFR to Modulate Antitumor Immunity / J. Yang, J. Yan, B. Liu // Front. Immunol.- 2018.- V.9.- P. 978.

The authors declare that there are no conflicts of interest present.